A doxorubicin–CNGRC-peptide conjugate with prodrug properties
Authors:
- Henk J. BroxtermanHBHenk J. Broxterman
- Yvonne W. ElderkampYEYvonne W. Elderkamp
- Jan LankelmaJLJan Lankelma
- Judith C.C. BeersJBJudith C.C. Beers
- Marc HeijnMHMarc Heijn
- Epie BovenEBEpie Boven
- Klaas HoekmanKHKlaas Hoekman
- Herbert M. PinedoHPHerbert M. Pinedo
- 1 March 2002
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 63 (5) , 897-908
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Anti-angiogenesis therapy:concepts and importance of dosing schedules in clinical trialsDrug Resistance Updates, 2000
- Liposomal formulations of anticancer drugs: selectivity and effectivenessDrug Resistance Updates, 2000
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityJournal of Clinical Investigation, 2000
- Anticancer drug targets: approaching angiogenesisJournal of Clinical Investigation, 1999
- Peptide-Guided Cancer Drugs Show Promise in MiceScience, 1998
- Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin.Journal of Clinical Pathology, 1994
- The monoclonal antibody ER‐BMDM1 recognizes a macrophage and dendritic cell differentiation antigen with aminopeptidase activityEuropean Journal of Immunology, 1992
- CD‐13 (‘gp150’; aminopeptidase‐N): Co‐expression on endothelial and haemopoietic cells with conservation of functional activityImmunology & Cell Biology, 1991
- Doxorubicin compared with related compounds in a nude mouse model for human ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N.Journal of Clinical Investigation, 1989